Try a new search

Format these results:

Searched for:



Total Results:


Quetiapine for primary insomnia: Consider the risks

Modesto-Lowe, Vania; Harabasz, Agata K; Walker, Sophia A
The second-generation antipsychotic drug quetiapine (Seroquel) is increasingly being used off-label for treating insomnia in the general population, possibly to avoid standard medications with known addictive qualities and adverse side effects. However, evidence to support using it in this way is scant, and quetiapine is associated with weight gain and other metabolic effects. It must be used cautiously and with appropriate monitoring for adverse effects and abuse.
PMID: 33941603
ISSN: 1939-2869
CID: 4969082

Pharmacogenomics: an Update for Child and Adolescent Psychiatry

Namerow, Lisa B; Walker, Sophia A; Loftus, Mirela; Bishop, Jeffrey R; RuaƱo, Gualberto; Malik, Salma
PURPOSE OF REVIEW:This paper aims to acquaint child and adolescent psychiatrists with the field of pharmacogenomics (PGX) and review the most up-to-date evidence-based practices to guide the application of this field in clinical care. RECENT FINDINGS:Despite much research being done in this area, the field of PGX continues to yield controversial findings. In the adult world, studies have focused on the impact of combinatorial gene panels that guide medication selection by providing reports that estimate the impact of multiple pharmacodynamic and pharmacokinetic genes, but to date, these have not been directly examined in younger patient populations. Pharmacokinetic genes, CYP2D6 and CYP2C19, and hypersensitivity genes, HLA-A and HLA-B, have the strongest evidence base for application to pharmacotherapy in children. Although the field is evolving, and the evidence is mixed, there may be a role for PGX testing in children to help guide dosing and monitoring strategies. However, evidence-based medicine, rather than PGX testing, continues to play the lead role in guiding medication selection in pediatric psychopharmacology.
PMID: 32377970
ISSN: 1535-1645
CID: 4969072